Table. 6—

Distribution of concomitant steroid use: clinical successes and microbiological eradications

Uncomplicated groupComplicated group
Levo.Azithro.p-valueLevo.Amox.p-value
Clinical success
 Clinically evaluable
  Acute steroid use12/15 (80.0)6/9 (66.7)0.63512/22 (54.5)12/20 (60.0)0.764
  No acute steroid use121/128 (94.5)130/142 (91.5)0.47683/98 (84.7)91/106 (85.8)0.845
 Microbiologically evaluable
  Acute steroid use5/5 (100)4/5 (80.0)1.0004/10 (40.0)6/13 (46.2)1.000
  No acute steroid use72/75 (96.0)72/82 (87.8)0.08366/76 (86.8)66/76 (86.8)1.000
Microbiological eradication
 Microbiologically evaluable
  Acute steroid use4/5 (80.0)3/5 (60.0)1.0005/10 (50.0)7/13 (53.8)1.000
  No acute steroid use71/75 (94.7)69/82 (84.1)0.04165/76 (85.5)64/76 (84.2)1.000
  • Data are presented as n/N (%), unless otherwise stated. Levo.: levofloxacin; azithro.: azithromycin; amox.: amoxicillin.